Shilpa Medicare Limited (SHILPAMED.BO)
INR 825.9
(-0.56%)
INR 825.9
(-0.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.06 Billion INR | 16.59% |
| 2022 | 7.77 Billion INR | 19.77% |
| 2021 | 6.49 Billion INR | -10.18% |
| 2020 | 7.23 Billion INR | 107.99% |
| 2019 | 3.47 Billion INR | 117.61% |
| 2018 | 1.59 Billion INR | 36.06% |
| 2017 | 1.17 Billion INR | -17.08% |
| 2016 | 1.41 Billion INR | 74.22% |
| 2015 | 812.83 Million INR | -5.34% |
| 2014 | 858.65 Million INR | -21.48% |
| 2013 | 1.09 Billion INR | -4.84% |
| 2012 | 1.14 Billion INR | 96.14% |
| 2011 | 585.9 Million INR | 294.79% |
| 2010 | -300.78 Million INR | -140.3% |
| 2009 | 746.37 Million INR | -31.29% |
| 2008 | 1.08 Billion INR | 47.37% |
| 2007 | 737.07 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 215.64 Million INR | -97.23% |
| 2023 Q2 | 8.41 Billion INR | 3803.19% |
| 2023 FY | 9.06 Billion INR | 16.59% |
| 2023 Q4 | 9.06 Billion INR | 3682.5% |
| 2023 Q3 | 239.77 Million INR | -97.15% |
| 2022 Q2 | 7.56 Billion INR | 1967.13% |
| 2022 Q1 | 365.73 Million INR | -94.37% |
| 2022 Q4 | 7.77 Billion INR | 1260.88% |
| 2022 FY | 7.77 Billion INR | 19.77% |
| 2022 Q3 | 571.6 Million INR | -92.44% |
| 2021 Q2 | 8.13 Billion INR | 561.2% |
| 2021 Q4 | 6.49 Billion INR | 1666.16% |
| 2021 FY | 6.49 Billion INR | -10.18% |
| 2021 Q1 | 1.23 Billion INR | -82.97% |
| 2021 Q3 | 367.72 Million INR | -95.48% |
| 2020 FY | 7.23 Billion INR | 107.99% |
| 2020 Q4 | 7.23 Billion INR | 269.4% |
| 2020 Q1 | 510.1 Million INR | -85.33% |
| 2020 Q3 | 1.95 Billion INR | -53.07% |
| 2020 Q2 | 4.17 Billion INR | 717.59% |
| 2019 Q2 | 2.11 Billion INR | 103.41% |
| 2019 FY | 3.47 Billion INR | 117.61% |
| 2019 Q1 | 1.04 Billion INR | -34.8% |
| 2019 Q4 | 3.47 Billion INR | 2261.62% |
| 2019 Q3 | 147.21 Million INR | -93.05% |
| 2018 Q1 | 2.04 Billion INR | 74.43% |
| 2018 FY | 1.59 Billion INR | 36.06% |
| 2018 Q4 | 1.59 Billion INR | -18.47% |
| 2018 Q3 | 1.95 Billion INR | 719.67% |
| 2018 Q2 | 239.06 Million INR | -88.33% |
| 2017 FY | 1.17 Billion INR | -17.08% |
| 2017 Q1 | 3.28 Billion INR | 132.18% |
| 2017 Q2 | 1.45 Billion INR | -55.74% |
| 2017 Q3 | 2.56 Billion INR | 76.38% |
| 2017 Q4 | 1.17 Billion INR | -54.26% |
| 2016 Q3 | 864.28 Million INR | 3.08% |
| 2016 FY | 1.41 Billion INR | 74.22% |
| 2016 Q4 | 1.41 Billion INR | 63.85% |
| 2016 Q2 | 838.42 Million INR | 0.0% |
| 2015 Q1 | 837.71 Million INR | -2.44% |
| 2015 FY | 812.83 Million INR | -5.34% |
| 2015 Q4 | 812.83 Million INR | 10.91% |
| 2015 Q3 | 732.87 Million INR | -58.34% |
| 2015 Q2 | 1.75 Billion INR | 110.01% |
| 2014 Q3 | 1.24 Billion INR | 7.06% |
| 2014 Q2 | 1.16 Billion INR | 499.75% |
| 2014 Q4 | 858.65 Million INR | -31.28% |
| 2014 Q1 | 194.59 Million INR | -82.21% |
| 2014 FY | 858.65 Million INR | -21.48% |
| 2013 Q2 | 626.98 Million INR | -22.32% |
| 2013 FY | 1.09 Billion INR | -4.84% |
| 2013 Q4 | 1.09 Billion INR | 166.03% |
| 2013 Q3 | 411.07 Million INR | -34.44% |
| 2013 Q1 | 807.14 Million INR | -29.76% |
| 2012 Q2 | 666.99 Million INR | 0.0% |
| 2012 FY | 1.14 Billion INR | 96.14% |
| 2012 Q4 | 1.14 Billion INR | 0.0% |
| 2011 FY | 585.9 Million INR | 294.79% |
| 2011 Q4 | 585.9 Million INR | 0.0% |
| 2010 FY | -300.78 Million INR | -140.3% |
| 2009 FY | 746.37 Million INR | -31.29% |
| 2008 FY | 1.08 Billion INR | 47.37% |
| 2007 FY | 737.07 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | -954.9 Million INR | 1049.789% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 3745.427% |
| Sigachi Industries Limited | 859.94 Million INR | -954.659% |
| Bal Pharma Limited | 1.26 Billion INR | -617.775% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 318.382% |
| Medico Remedies Limited | 78.67 Million INR | -11427.551% |
| Lasa Supergenerics Limited | 205.79 Million INR | -4306.985% |
| Venus Remedies Limited | -267.7 Million INR | 3487.946% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 1063.0% |
| Alpa Laboratories Limited | 35.36 Million INR | -25546.95% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -47.297% |
| Aarti Drugs Limited | 5.54 Billion INR | -63.462% |
| Lupin Limited | 17.19 Billion INR | 47.247% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -145.567% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -131.839% |
| Windlas Biotech Limited | -273.04 Million INR | 3421.686% |
| Suven Life Sciences Limited | -1.63 Billion INR | 655.493% |
| Eris Lifesciences Limited | 13.8 Billion INR | 34.309% |
| Valiant Laboratories Limited | -295.03 Million INR | 3174.084% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -221.478% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 9.567% |
| Ipca Laboratories Limited | 11.41 Billion INR | 20.549% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 883.374% |
| Achyut Healthcare Limited | -3.74 Million INR | 242212.413% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 112.515% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -174.921% |
| RPG Life Sciences Limited | -364.7 Million INR | 2586.847% |
| Mankind Pharma Limited | -9.9 Billion INR | 191.538% |
| Laurus Labs Limited | 24.38 Billion INR | 62.806% |
| Piramal Pharma Limited | 42.27 Billion INR | 78.547% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -19526.347% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 71.506% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -134.603% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 311.645% |
| Unichem Laboratories Limited | 931.91 Million INR | -873.213% |
| Sequent Scientific Limited | 4.17 Billion INR | -117.046% |
| Novartis India Limited | -5.89 Billion INR | 253.953% |
| Wanbury Limited | 1.1 Billion INR | -720.123% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -6155.884% |
| Wockhardt Limited | 18.27 Billion INR | 50.358% |
| Themis Medicare Limited | 764.96 Million INR | -1085.619% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 752.517% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 66.498% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 419.051% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 29.764% |
| Divi's Laboratories Limited | -39.77 Billion INR | 122.805% |
| NATCO Pharma Limited | -5.81 Billion INR | 255.914% |
| Gufic Biosciences Limited | 3.19 Billion INR | -183.927% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 923.53% |
| Ind-Swift Limited | 9.5 Billion INR | 4.617% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 486.266% |
| FDC Limited | -57.75 Million INR | 15804.272% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -369.214% |
| Granules India Limited | 9.28 Billion INR | 2.339% |
| Medicamen Biotech Limited | 160.31 Million INR | -5557.284% |
| Alkem Laboratories Limited | -1.6 Billion INR | 663.535% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 280.94% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 49268.009% |
| Brooks Laboratories Limited | 49.48 Million INR | -18227.839% |
| Megasoft Limited | 1.28 Billion INR | -605.497% |
| ZIM Laboratories Limited | 983.6 Million INR | -822.071% |
| Strides Pharma Science Limited | 23.25 Billion INR | 61.003% |
| Neuland Laboratories Limited | -214.05 Million INR | 4336.95% |
| Morepen Laboratories Limited | -231.17 Million INR | 4023.249% |
| Hikal Limited | 7.96 Billion INR | -13.839% |
| Indoco Remedies Limited | 6.47 Billion INR | -40.042% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -247.239% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -7455.487% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -829.435% |
| Hester Biosciences Limited | 2.29 Billion INR | -295.921% |